FILTER
FILTERED INTERVIEW RESULTS
Jay A. Roberts
PRESIDENT & CEO, CANCER GENETICS, INC.
Cancer Genetics has merged with StemoniX and is addressing the challenges of drug discovery using innovative, science-based technologies and a highly-developed focus on the regulatory community.
Kendalle O’Connell
PRESIDENT AND COO, MASSBIO
MassBio explains how it intends to ensure that Massachusetts remains a global leader for life sciences.
Daphne Zohar & Bharatt Chowrira
FOUNDER AND CEO & PRESIDENT AND CHIEF OF BUSINESS AND STRATEGY, PURETECH HEALTH
PureTech Health is expanding swiftly with 24 product candidates that it has invented or initiated, 13 of which are in clinical testing, and two have received FDA clearance.
Peter DeYoung
CEO, PIRAMAL GLOBAL PHARMA
Piramal Global Pharma is responding to growing demand with rapid expansion in the CDMO space.
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
PBOA explains why the CDMO sector enjoys a higher profile.
Debbie Hart
FOUNDING PRESIDENT & CEO, BIONJ
BioNJ relates how New Jersey’s thriving life sciences sector is benefitting from a tremendous boost.
Chris Garabedian
CHAIRMAN & CEO, XONTOGENY
Xontogeny explains how it can help young companies to cross the valley of death.
Rajiv Anand
FOUNDER AND CEO, QUARTIC.AI
Quartic AI explains how artificial intelligence and machine learning should be applied in life sciences.
Rajiv Anand
FOUNDER & CEO, QUARTIC AI
"Much of the focus of tech development has been for people in IT and data science. This creates a big barrier to adoption for chemists, biologists or chemical engineers, it is unsustainable. Overcoming those two barriers is the inspiration behind Quartic.ai."
Peter Staartjes
CEO, ANDINO HOLDINGS
Andino Holdings comments on the factors influencing the chemical distribution market in Latin America for 2020.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
